查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1638796

2024 - 2032 年解剖病理學市場機會、成長促進因素、產業趨勢分析與預測

Anatomic Pathology Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年全球解剖病理學市場價值約為 367 億美元，預計 2024 年至 2032 年複合年成長率為 7.8%。 。利用組織病理學、細胞病理學和屍檢病理學等技術，解剖病理學家在細胞層面分析樣本，揭示疾病過程引起的結構和功能變化。

疾病，特別是癌症的日益流行，推動了對解剖病理學服務的巨大需求。隨著全球疾病負擔的增加，對精確診斷工具的需求激增。組織病理學和細胞病理學等技術對於準確的疾病檢測和管理、推動市場成長至關重要。此外，生物標記的廣泛使用、病理設備的進步以及臨床試驗的增加都提高了診斷的準確性和可靠性。數位病理學等技術進一步支持診斷的效率和準確性，促進該行業的成長。

基於產品和服務的市場區隔包括儀器、消耗品和服務。消耗品領域在2023年創造了192億美元的收入，引領市場，預計將保持強勁成長。精密玻片和試劑等高品質消耗品對於提高整個實驗室的診斷準確性和標準化至關重要。即用型耗材使技術人員能夠專注於樣本分析，從而提高工作流程效率，最大限度地減少準備時間並提高實驗室生產力。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 367 億美元
預測值 719 億美元
複合年成長率 7.8%

按應用分類，市場分為疾病診斷和研究，其中疾病診斷，特別是癌症診斷，將在2023 年佔據相當大的市場佔有率。價值的見解，有助於準確診斷。與基因組學和蛋白​​質組學等分子測試技術的整合，透過將診斷結果與遺傳和生物標記資料結合起來，進一步增強個人化醫療。

到 2023 年，醫院的最終用途部分將佔據 55.4% 的佔有率，並有望大幅成長。醫院受益於廣泛的診斷工具，可以採用全面的患者護理方法。先進的分子檢測與解剖病理學相結合，使醫院能夠提供個人化治療，尤其是腫瘤學治療，從而提高治療效果和患者滿意度。

在北美，由於疾病盛行率高且完善的醫療基礎設施，美國在解剖病理學市場中處於領先地位。包括數位病理學和人工智慧驅動工具在內的先進診斷技術已被廣泛採用，提高了診斷準確性並改善了患者的整體護理。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 全球癌症和其他目標疾病的發生率不斷上升
      • 擴大採用生物標記
      • 與癌症藥物相關的臨床試驗數量不斷增加
      • 病理設備技術不斷進步
    • 產業陷阱與挑戰
      • 設備成本高
      • 翻新解剖病理學系統的可用性
  • 成長潛力分析
  • 監管環境
  • 技術景觀
    • 核心技術
    • 鄰近技術
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品和服務分類，2021 - 2032 年

  • 主要趨勢
  • 儀器儀表
    • 切片機
    • 細胞處理器
    • 組織處理系統
    • 玻片染色系統
    • 包埋系統
    • 蓋玻片
    • 其他儀器
  • 耗材
    • 抗體
      • 一抗
      • 二抗
    • 試劑盒和試劑
      • 污漬和溶劑
      • 固定劑
      • 其他試劑盒和試劑
    • 探頭
    • 其他消耗品
  • 服務
    • 組織病理學
    • 細胞病理學

第 6 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 疾病診斷
    • 癌症
      • 乳癌
      • 胃腸癌
      • 肺癌
      • 攝護腺癌
      • 其他癌症類型
    • 其他疾病
  • 研究

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 診斷中心
  • 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 9 章：公司簡介

  • Supply-side
  • Demand-side (Laboratories)
簡介目錄
Product Code: 12097

The Global Anatomic Pathology Market, valued at around USD 36.7 billion in 2023, is projected to grow at a CAGR of 7.8% from 2024 to 2032. Anatomic pathology, a specialized branch of pathology, focuses on diagnosing diseases by examining surgical specimens, tissues, and organs. Utilizing techniques like histopathology, cytopathology, and autopsy pathology, anatomic pathologists analyze samples at a cellular level, uncovering structural and functional changes caused by disease processes.

The growing prevalence of diseases, particularly cancer, drives significant demand for anatomic pathology services. With an increasing disease burden worldwide, the need for precise diagnostic tools has surged. Techniques like histopathology and cytopathology are critical for accurate disease detection and management, fueling market growth. Furthermore, the expanding use of biomarkers, advancements in pathology equipment, and the rise in clinical trials are all enhancing diagnostic precision and reliability. Technologies like digital pathology further support the efficiency and accuracy of diagnoses, contributing to the sector's growth.

Market segments based on products and services include instruments, consumables, and services. The consumables segment, which generated USD 19.2 billion in revenue in 2023, led the market and is anticipated to maintain robust growth. High-quality consumables, such as precision slides and reagents, are essential for improving diagnostic accuracy and standardization across labs. Ready-to-use consumables enhance workflow efficiency, minimizing preparation time and improving lab productivity by enabling technicians to focus on specimen analysis.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$36.7 Billion
Forecast Value$71.9 Billion
CAGR7.8%

By application, the market is divided into disease diagnostics and research, with disease diagnostics, particularly cancer diagnostics, holding a substantial market share in 2023. Anatomic pathology enables detailed tissue and cell analysis, providing valuable insights into disease morphology, which aids in accurate diagnosis. Integration with molecular testing techniques, like genomics and proteomics, further enhances personalized medicine by aligning diagnostic findings with genetic and biomarker data.

The end-use segment of hospitals held a 55.4% share in 2023 and is poised for substantial growth. Hospitals benefit from access to a broad range of diagnostic tools, allowing for a comprehensive approach to patient care. Advanced molecular testing, combined with anatomic pathology, enables hospitals to offer personalized treatments, especially for oncology, thus enhancing treatment outcomes and patient satisfaction.

In North America, the U.S. leads the anatomic pathology market due to high disease prevalence and a well-established healthcare infrastructure. Advanced diagnostic technologies, including digital pathology and AI-driven tools, are widely adopted, boosting diagnostic accuracy and enhancing overall patient care.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of cancer and other target diseases worldwide
      • 3.2.1.2 Growing adoption of biomarkers
      • 3.2.1.3 Increasing number of clinical trials pertaining to cancer drugs
      • 3.2.1.4 Increasing technological advancements of pathology equipment
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of equipment
      • 3.2.2.2 Availability of refurbished anatomic pathology systems
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product and Service, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
    • 5.2.1 Microtomes
    • 5.2.2 Cell processors
    • 5.2.3 Tissue processing systems
    • 5.2.4 Slide staining systems
    • 5.2.5 Embedding systems
    • 5.2.6 Coverslippers
    • 5.2.7 Other instruments
  • 5.3 Consumables
    • 5.3.1 Antibodies
      • 5.3.1.1 Primary antibodies
      • 5.3.1.2 Secondary antibodies
    • 5.3.2 Kits and reagents
      • 5.3.2.1 Stains and solvents
      • 5.3.2.2 Fixatives
      • 5.3.2.3 Other kits and reagents
    • 5.3.3 Probes
    • 5.3.4 Other consumables
  • 5.4 Services
    • 5.4.1 Histopathology
    • 5.4.2 Cytopathology

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Diseases diagnostics
    • 6.2.1 Cancer
      • 6.2.1.1 Breast cancer
      • 6.2.1.2 Gastrointestinal cancer
      • 6.2.1.3 Lung cancer
      • 6.2.1.4 Prostate cancer
      • 6.2.1.5 Other cancer types
    • 6.2.2 Other diseases
  • 6.3 Research

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic centers
  • 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Supply-side
    • 9.1.1 Agilent Technologies
    • 9.1.2 Becton, Dickinson and Company
    • 9.1.3 Cardinal Health
    • 9.1.4 Danaher Corporation
    • 9.1.5 F. Hoffmann-La Roche
    • 9.1.6 Merck
    • 9.1.7 Thermo Fisher Scientific
  • 9.2 Demand-side (Laboratories)
    • 9.2.1 Ampath Laboratories
    • 9.2.2 Al Borg Medical Laboratories
    • 9.2.3 Biolab
    • 9.2.4 Eurofins Scientific
    • 9.2.5 Laboratoires Reunis
    • 9.2.6 Lifebrain Group
    • 9.2.7 Lancet Laboratories
    • 9.2.8 Medsol Diagnostics
    • 9.2.9 Synlab Group
    • 9.2.10 Unilabs